Riskpilot← Back to searchSign inGet full accessDroMed A&R AB
ABActiveOrg 5566625249Tegnérlunden 14Business and other management consultancy activities · NACE 7020Est. 20040 employees
Revenue 2025
SEK 0
EBITDA margin
—
-26% vs 2024
Equity ratio
-1161.0%
Financial strength
Net profit 2025
SEK -16K
-26% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -16K | -26% |
| Net profit | SEK -16K | -26% |
| Total assets | SEK 10K | -3% |
| Equity | SEK -121K | -15% |
| Employees | 0 | — |
Legal name
DroMed A&R AB
Org number
5566625249
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
25 maj 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva forskning, utveckling, utbildning och konsultverksamhet inom området medicin även läkarverksamhet samt utveckla och driva patent inom samma område, samt idka därmed förenlig verksamhet.
Address
Tegnérlunden 14
Phone
+46708709088
Email
dan.drobin@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −20 | −12 | −18 | −13 | −16 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −20 | −12 | −18 | −13 | −16 |
| Net financials | — | — | 0 | 0 | 0 |
| Profit before tax | −20 | −12 | −18 | −13 | −16 |
| Tax | −0 | — | — | — | — |
| Net profit | −20 | −12 | −18 | −13 | −16 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 11 | 12 | 8 | 11 | 10 |
| Equity | −62 | −75 | −93 | −105 | −121 |
| Long-term debt | 68 | 82 | 96 | — | — |
| Short-term debt | 5 | 5 | 5 | 116 | 132 |
| Total debt | 73 | 87 | 101 | 116 | 132 |
EBITDA margin
-1590700.0%
This company
15.8%
Market median
-10067822% vs market
20212025
Equity ratio
-1161.0%
This company
38.2%
Market median
-3139% vs market
20212025
Return on equity
-1577700.0%
This company
18.4%
Market median
-8574557% vs market
20212025
Net profit margin
-1577700.0%
This company
8.1%
Market median
-19477878% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
1.09×
This company
0.62×
Market median
-76% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DR Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of DroMed A&R AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dan Roland Drobin | Chief Executive Officer | 0 companies |
| Lisa Maria Michaela Zankl | Deputy Board Member | 0 companies |